

Others | Pharmaceuticals

November 02, 2018

Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals is the pharma arm of the Torrent Group. The company specializes in cardiovascular, diabetes and central nervous system (CNS). Chronic and sub-chronic therapies form 75% of the portfolio (52% of Indian pharma market). Nearly 39% of the revenue is generated domestically while the rest is earned from US, Germany, Brazil and ROW markets. Torrent Pharma made 5 acquisitions since 2014. The latest one, Unichem Laboratories, helped the company in elevating its position among peers to number 5 from number 13. Torrent-Unichem integration will be completed by FY19. The company expects further synergies from this acquisition. It also expects \sim 25% growth from the US market. Currently, Torrent has 51 US ANDA monetisation in the pipeline, which was just 16 in FY16. Further, it plans to launch 8-9 products in FY19. The company has made huge investment in FY18 in capacity expansion and acquisitions. An investment in caopex worth ₹2 bn is also planned for FY19, which is expected to increase production. Revenues and profits of the company are growing at a healthy rate. It registered an 18.1% and 19.1% CAGR in sales and PAT over FY2009-18. Torrent Pharma has also delivered 3-year average ROE of 29.4%. Hence Buy.

BUY	
CMP	₹1,630

Stock Info	
Sector	Pharmaceuticals
Market Cap (₹ cr)	27,589
52 Week High / Low	1962/1221
Avg. Daily Volume	7,053
Face Value (₹)	5
BSE Sensex	35,012
Nifty	10,553
Reuters Code	torp.bo
Bloomberg Code	TRP IN

Shareholding Pattern (%)		
Promoters	71.3	
MF / Banks / Indian Fls	10.9	
FII / NRIs / OCBs	8.1	
Indian Public / Others	9.7	

Abs. (%)	3m	1yr	Зуr
Sensex	(5.8)	4.3	31.8
Torrent	7.1	23.0	6.0

Jaikishan Parmar 022 - 3935 7600 Ext: 6810 jaikishan.parmar@angelbroking.com



Research Team Tel: 022 - 39357600

E-mail: research@angelbroking.com

Website: www.angelbroking.com

DISCLAIMER

Angel Broking Limited (hereinafter referred to as "Angel") is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and Metropolitan Stock Exchange Limited. It is also registered as a Depository Participant with CDSL and Portfolio Manager with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel Broking Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000000164. Angel or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market. Angel or its associates/analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months.

This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Investors are advised to refer the Fundamental and Technical Research Reports available on our website to evaluate the contrary view, if any.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly.

Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

Disclosure of Interest Statement		т	orrent Pharmaceuticals
1. Financial interest of research analyst or Angel or his Associate or his relative		s relative	No
2. Ownership of 1% or more of the stock by research analyst or Angel or associates or relatives			No
3. Served as an officer, director or employee of the company covered under Research		under Research	No
4. Broking relationship with company covered under Research		No	
Ratings (Based on expected returns over 12 months investment period):	Buy (> 15%)	Accumulate (5% to 15 Reduce (-5% to -15%)	· · · · ·